CD274 and ovarian carcinoma: During the phase 1 clinical trial (NCT01772004) of the PD-L1 inhibitor, avelumab, the researchers noted that 125 patients with the relapsed or refractory epithelial ovarian cancer showed a 1-year progression-free survival rate of 10.2%.